Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS<sup>G12C</sup></i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.

导出 OA

翻译打印收藏纠错

第一作者： Marcelo V,Negrao

第一单位： Department of Thoracic/Head & Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX.

作者： Marcelo V,Negrao ^[1] ; Alexander I,Spira ^[2] ; Rebecca S,Heist ^[3] ; Pasi A,Jänne ^[4] ; Jose M,Pacheco ^[5] ; Jared,Weiss ^[6] ; Shirish M,Gadgeel ^[7] ; Karen,Velastegui ^[8] ; Wenjing,Yang ^[9] ; Hirak,Der-Torossian ^[10] ; James G,Christensen ^[10] ; Joshua K,Sabari ^[10]

作者单位： Department of Thoracic/Head & Neck Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX. ^[1] Virginia Cancer Specialists, Fairfax, VA. ^[2] US Oncology Research, The Woodlands, TX. ^[3] NEXT Oncology, Fairfax, VA. ^[4] Massachusetts General Hospital, Boston, MA. ^[5] Dana-Farber Cancer Institute, Boston, MA. ^[6] Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO. ^[7] Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC. ^[8] Henry Ford Cancer Institute, Detroit, MI. ^[9] Mirati Therapeutics, Inc, San Diego, CA. ^[10] Perlmutter Cancer Center, New York University Langone Health, New York, NY. ^[11]